Talphera Inc. Announces $29 Million Private Placement Financing with Strategic Investment from CorMedix
Reuters
Sep 08
<a href="https://laohu8.com/S/TLPH">Talphera Inc.</a> Announces $29 Million Private Placement Financing with Strategic Investment from CorMedix
Talphera, Inc. (Nasdaq: TLPH), a specialty pharmaceutical company, has announced a securities purchase agreement with CorMedix Inc. and certain institutional investors. The agreement involves the sale and issuance of common stock and pre-funded warrants for potential proceeds of up to $29 million. In the initial closing, Talphera will issue over 25 million shares of common stock and nearly 6 million pre-funded warrants. An additional tranche of $12 million in shares and warrants is contingent upon the achievement of specific milestones in the NEPHRO CRRT clinical study and the company's stock trading at a minimum agreed price. CorMedix will make a strategic investment, with the institutional investors purchasing at market prices. The deal is structured as a private placement under the Securities Act of 1933.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Talphera Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF67432) on September 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.